Gemphire Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
August 01, 2017 16:30 ET
|
Gemphire Therapeutics
LIVONIA, Mich., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), today announced that on July 31, 2017, the Compensation Committee of its Board of Directors, which is...
Gemphire Enters Into $15 Million Term Loan Agreement With Silicon Valley Bank
July 25, 2017 08:00 ET
|
Gemphire Therapeutics
LIVONIA, Mich., July 25, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP) today announced that it has entered into a loan and security agreement with Silicon Valley Bank for a term...
Gemphire Announces Top-Line Data from COBALT-1 Phase 2b Clinical Trial in HoFH Patients
June 28, 2017 16:01 ET
|
Gemphire Therapeutics
Gemcabene achieves primary endpoint for LDL cholesterol in phase 2b HoFH trial Company to host conference call at 4:30 pm ET today LIVONIA, Mich., June 28, 2017 (GLOBE NEWSWIRE) -- Gemphire...
Gemphire to Present at the LD Micro Invitational and the Jefferies 2017 Global Healthcare Conference
June 01, 2017 08:00 ET
|
Gemphire Therapeutics
LIVONIA, Mich., June 01, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...
Gemphire Therapeutics Announces Departure of Its Chief Executive Officer Mina Sooch
May 30, 2017 16:01 ET
|
Gemphire Therapeutics
LIVONIA, Mich., May 30, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (Nasdaq:GEMP) announced today that Mina Sooch, President, CEO, and Director of the Company has resigned for personal...
Gemphire Announces First Quarter 2017 Financial Results and Provides Corporate Update
May 09, 2017 06:00 ET
|
Gemphire Therapeutics
LIVONIA, Mich., May 09, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...
Gemphire to Host Key Opinion Leader Lunch on the Evolving NASH Landscape
May 04, 2017 14:21 ET
|
Gemphire Therapeutics
LIVONIA, Mich., May 04, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...
Gemphire to Present at ATVB|PVD 2017 Scientific Sessions
May 01, 2017 06:00 ET
|
Gemphire Therapeutics
LIVONIA, Mich., May 01, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), today announced that it will present a poster on gemcabene’s mechanism of action based on recent...
Gemphire Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
March 29, 2017 16:30 ET
|
Gemphire Therapeutics
LIVONIA, Mich., March 29, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), today announced that on March 28, 2017, the Compensation Committee of its Board of Directors, which is...
Gemphire Therapeutics Announces Presentation at ACC Meeting of Phase 2 Clinical Trial Investigating Effect of Gemcabene on Insulin Sensitization
March 21, 2017 09:16 ET
|
Gemphire Therapeutics
LIVONIA, Mich., March 21, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...